Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged Semaglutide.
A new ENDO 2026 wearable-data study found GLP-1 users lost weight but moved less. Alex Keane explains why steps, resistance training, and muscle protection now matter.
GLP-1 cancer risk is suddenly a mainstream question. Alex Keane explains what the newest studies suggest, what they do not prove, and why peptide biology matters.
The viral Ozempic lizard venom story points to real peptide science. Learn how exendin-4, exenatide, and semaglutide fit together.
Retatrutide search interest is rising alongside GLP-1 hype. Here is what the evidence says, what remains investigational, and why gray-market peptides are risky.
GLP-1 drugs and retatrutide are suddenly part of the knee osteoarthritis conversation. Here is what the peptide science says, and what remains unproven.
GLP-1 muscle loss is today’s peptide-health conversation because apitegromab, a myostatin-targeting antibody, just showed early evidence of preserving lean mass during tirzepatide weight loss.
No articles match that search.